


Name of Policy: <u>Investigation of Suspected Transfusion-Transmitted Disease</u> Policy Number: 3364-108-502 Department: Pathology/Laboratory – Blood Bank Approving Officer: Associate Professor Director, Clinical Pathology/Hematopathology Responsible Agent: Core Lab Coordinator (Michelle Bartkowiak, MT(ASCP)SBB) Manager, Lab (Cynthia O’Connell) Scope: Pathology/Laboratory – Blood Bank			
	Effective Date: 6/9/2008 Initial Effective Date: 10/1986		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;"> <input type="checkbox"/> New policy proposal <input type="checkbox"/> Major revision of existing policy </td> <td style="width: 50%; border: none;"> <input type="checkbox"/> Minor/technical revision of existing policy <input checked="" type="checkbox"/> Reaffirmation of existing policy </td> </tr> </table>		<input type="checkbox"/> New policy proposal <input type="checkbox"/> Major revision of existing policy	<input type="checkbox"/> Minor/technical revision of existing policy <input checked="" type="checkbox"/> Reaffirmation of existing policy
<input type="checkbox"/> New policy proposal <input type="checkbox"/> Major revision of existing policy	<input type="checkbox"/> Minor/technical revision of existing policy <input checked="" type="checkbox"/> Reaffirmation of existing policy		

(A) Policy Statement


The Blood Transfusion Service investigates and evaluates cases of suspected transfusion-transmitted disease.

(B) Purpose of Policy

To indicate the need for patient care in confirmed cases of disease transmission and to identify blood products and donors carrying transfusion-transmitted disease.

(C) Procedure

1. Infection Control identifies cases of suspected transfusion-transmitted disease and reports such cases to the Blood Transfusion Service Medical Director.
2. Infection Control reviews the patient record for history of derivative transfusion and dialysis.
3. The Blood Transfusion Service determines the unit numbers of blood products transfused to the patient and the dates of these transfusions.
4. If blood components or derivatives are suspected or identified as the source of infection, the Blood Transfusion Service Medical Director or Director of Clinical Laboratories notifies the Medical Director of the American Red Cross Blood Services by established protocol. See ARC Adverse Effects Reporting File.

Approved by:  <hr/> Robert L. Booth, Jr., M.D. Associate Professor Director, Clinical Pathology/Hematopathology Review/Revision Completed By: Michelle Bartkowiak, MT(ASCP)SBB	Review/Revision Date: 6/96 2/99 1/05 12/07 6/9/2008 Next Review Date: 6/1/2011
Policies Superseded by This Policy:	

It is the responsibility of the reader to verify with the responsible agent that this is the most current version of the policy.

Reference: AABB Standards for Blood Banks and Transfusion Services, Current Edition